Ramy Sedhom, MD, FASCO

Director, Center for Cancer & Aging at Penn
Dreamer / Developer of Systems focused on Patient-Centered Care

[Ramy Sedhom, MD, FASCO @ramsedhom]

Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us.

Read our opinion piece in @JCO_ASCO
https://t.co/UFuxuDI3sn

[Common Sense Oncology @csoncol]

Join CSO on November 16th for a critical appraisal of the RASolute 302 trial, followed by a discussion of how the pricing of daraxonrasib will impact patient access.

Where: Online (Zoom)
When: Monday, November 16, 2026 at 2:00 pm (EST) / 1:00 pm (CST) / 12:00 pm (MST)
Speakers: Dr. Ian Tannock, Dr. Chris Booth, Dr. Sharlene Gill, Carolyn Taylor, Dr. Ramy Sedhom

Register now: https://t.co/4PnvFG21Cn

#CommonSenseOncology #CancerCare #Daraxonrasib

[Yara Abdou, MD, MSCR @YAbdouMD]

Proudly voting for @minasedrakmd and @RManochakian !! Incredible physicians and wonderful human beings.

So proud to see fellow Middle Eastern oncologists leading the way!

Please vote and show your support🗳️

[Mina S. Sedrak @minasedrakmd]

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit https://t.co/4MzXWlDLiy to learn more about the candidates and place your vote!

[Mina S. Sedrak @minasedrakmd]

Thank you for sharing! Grateful to @NCIDirector @theNCI for this new R01! Many older adults struggle to regain strength after transplant. We hope this work helps them recover faster and live well. Grateful for my Co-PIs @ArmenianSaro and Kirsten Ness. Both are helping bring concepts from Pediatrics Oncology to #GeriOnc.

[Mina S. Sedrak @minasedrakmd]

20 randomized ADC trials. More than 13,000 participants. Not one told us whether ADCs are as safe and tolerable for older adults (≥65y) with breast cancer.

Benefit was similar across ages. But no trial reported toxicity by both age and treatment arm.

So proud of @sammargolis_ , a 3rd-year med student who led this, with @hoperugo and @dradityabardia in @JNCI_Now

https://t.co/cL7Zfi0l5D

[Penn Medicine Cancer @PennCancer]

.@ramsedhom discussed strategies for bridging historical silos between palliative care & psycho-oncology, debunked persistent misconceptions surrounding supportive interventions in curative settings, and more. @OncNursingNews https://t.co/AngLOjRkUw

[Dr Sarah Sammons @drsarahsam]

First prospective switch trial of Top1 ADC post Top1 ADC in MBC.

0-8% ORR

Switching target with same payload simply does not work.

Resistance is in payload.

Let’s stop talking about “sequencing”. It simply does not work. We need new payloads.

#MBC #BCSM #ESMO26

[Mohamed Osman @MHosmanMD]

Really enjoyed this conversation! Thanks @ramsedhom for such a thoughtful and insightful discussion.

[CancerNetwork® @CancerNetwrk]

🎧 Should patients wait months for mental health support after a cancer diagnosis? Daniel C. McFarland, DO, and @ramsedhom , explain how co-located teams and warm handoffs meet distress in real time.
https://t.co/ZhUGqsgdev

#OncTwitter #psychoonc #PalliativeCare

[Ramy Sedhom, MD, FASCO @ramsedhom]

Loved the opportunity to discuss whole person cancer care !

https://t.co/6sOJZd3Qfp

[Mina S. Sedrak @minasedrakmd]

“Chemo brain” is one of the most common things my patients ask me about. We still have no proven drug to treat it.

In our small phase II trial, breast cancer survivors with cognitive complaints took oxaloacetate for 8 weeks. Every participant who completed the study reported improvement in cognition, along with less fatigue and better physical function.

It’s an early signal, not an answer. A randomized, placebo-controlled trial is the next step.

Led by Dr. Patti Ganz, with thanks to @BCRFcure. Out now in @JCOOA_ASCO.

https://t.co/elZeSgr8C6 #bcsm

[Ramy Sedhom, MD, FASCO @ramsedhom]

@davidjeinstein @CaPsurvivorship Thank you! High praise as I’ve been a fan of your collective work

[David Einstein @davidjeinstein]

Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.

[Ramy Sedhom, MD, FASCO @ramsedhom]

"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."

Our piece - The commodification of Time Toxicity In Oncology
https://t.co/UhSEU8daxg

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Outstanding presentation by @minasedrakmd at @ASCO Quality Care Symposium today!

“Beyond the Guidelines: Caring for Older Adults With Cancer.”

https://t.co/CVwhdtrTau

#ASCOQLTY26 #GeriOnc

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

@minasedrakmd highlights the importance of translating evidence into personalized, patient-centered care for older adults with cancer.

How do we bridge the gap between recommendations and real-world practice?

#ASCOQLTY26

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

"'Tolerated' doesn't much at all". @itsnot_pink #ASCOQLTY26 on the importance of right sizing care for patients and the lived experience of cancer treatment and survivorship.

"Right-sized care starts with a conversation about what matters, right now."

[Ramy Sedhom, MD, FASCO @ramsedhom]

@minasedrakmd Thank you brother for all your guidance in moving our center and projects along, and your personal mentorship & friendship!

[Ramy Sedhom, MD, FASCO @ramsedhom]

@crisbergerot @ASCO @PauloBergerot @realbowtiedoc @JamesFanWu @DarcyBurbage @RyanNipp @fumikochino @WhatsUrHari Thank you for highlighting!!! Hope you had a chance to meet Kara at the Poster she’s terrific

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

From grant to sustainable clinical care! @ramsedhom

At #ASCOQLTY26, an integrated psychosocial oncology program in community cancer care reported 487 referrals, >97% patient satisfaction & 86% provider satisfaction